Safety outcomes: serious adverse events with obinutuzumab
| Dose level, mg . | SAE* . | |
|---|---|---|
| Diagnosis . | Event . | |
| 100/200 | SLL | Tumor flare |
| FL | Pneumonia/sinusitis | |
| 400/800 | FL | Infusion-related reaction |
| MCL | Febrile neutropenia | |
| CLL | Infusion-related reaction | |
| DLBCL | Malignant hypercalcaemia | |
| 1200/2000 | CLL | Pelvic fracture |
| Dose level, mg . | SAE* . | |
|---|---|---|
| Diagnosis . | Event . | |
| 100/200 | SLL | Tumor flare |
| FL | Pneumonia/sinusitis | |
| 400/800 | FL | Infusion-related reaction |
| MCL | Febrile neutropenia | |
| CLL | Infusion-related reaction | |
| DLBCL | Malignant hypercalcaemia | |
| 1200/2000 | CLL | Pelvic fracture |
Data are as of the August 2010 cutoff.
SLL indicates small lymphocytic lymphoma; MCL, mantle cell lymphoma; CLL, chronic lymphocytic leukemia; and DLBCL, diffuse large B cell lymphomia.
All SAEs resolved.